GIST
Conditions
Keywords
GIST, Gastro Intestinal Stromal Tumor
Brief summary
This is a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes. Moreover, a dedicated effort will be pursued to identify the peculiar characteristics (if any) of patients that experienced recurrence of the disease. The study will collect data about patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020
Detailed description
In the field of soft tissue sarcomas, Gastrointestinal Stromal Tumors (GIST) represents a really peculiar neoplasm for its biological and clinical properties. Surgery (if feasible) is the main therapeutic approach for all the patients with localized disease, while a pharmacological adjuvant treatment is reserved to those with a relevant risk of recurrence/progression. After tumor removal, clinical and radiological follow-up is of central importance to early intercept recurrence and to evaluate the most correct subsequent therapeutic approach. In particular, for the group of patients with GIST at very-low and low risk of recurrence/progression, the evidences to support a specific follow-up program and its features are poor. On the basis of the aforementioned considerations, we propose a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes. Moreover, a dedicated effort will be pursued to identify the peculiar characteristics (if any) of patients that experienced recurrence of the disease. The study will collect data about patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020
Interventions
OTHERTreatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)
This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
Sponsors
Italian Sarcoma Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>18 years at diagnosis * primary GIST removed by surgery or endoscopic procedures * availability of medical data needed for the study * very-low and low risk GIST defined as: * largest size of \< 3 cm (for all sites of origin) * gastric GIST with ≤ 5/50 High Power Fields (HPF) mitoses and ≤ 10 cm in the largest size * gastric GIST with \> 5/50 HPF mitoses and ≤ 5 cm in the largest size * intestinal GIST with ≤ 5/50 HPF mitoses and ≤ 5 cm in the largest size
Exclusion criteria
* Metastases at diagnosis. * Previous treatment with imatinib
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To describe the most relevant features of follow-up in very-low and low risk GIST patients | Change from diagnosis (baseline) | Collection of retrospectively imaging characteristics |
| To evaluate the onset of other neoplasms in very-low and low risk GIST patients | Chage from baseline (time of diagnosis) at 5 years | Onset of other neoplasm will be recoreded |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post-recurrence progression-free survival (PR-PFS) | Every 3 months (Month 3, Month 6, Month 9...) up to 5 years | Time elapsed form the onset of 1st progression to a further progression |
| To assess baseline clinical and disease-specific factors with possible impact on survival analyses. | Every 3 months (Month 3, Month 6, Month 9...) up to 5 years | Collection of clinical symptoms, pathological and molecular characteristics at disease presentation/diagnosis |
| Overall survival (OS). | at 5 years | Time elapsed for the diagnosis to the death for any cause |
| Disease-Specific survival (DSS) | at 5 years | Time elapsed for the diagnosis to the death of disease |
| Recurrence-free survival (RFS) | Every 3 months (Month 3, Month 6, Month 9...) up to 5 years | Time elapsed form the treatment (any) start and the onset of recurrence |
Countries
Italy
Outcome results
None listed